SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 [Yahoo! Finance]
SCYNEXIS, Inc. (SCYX)
Last scynexis, inc. earnings: 11/12 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.scynexis.com/investor-relations
Company Research
Source: Yahoo! Finance
Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration (“FDA”) has granted the Company Qualified Infectious Disease Product (QIDP) and Fast Track Designations for its second-generation triterpenoid antifungal therapy, SCY-247. “Receiving FDA's QIDP and Fast Track designations for SCY-247 reflects the potential of SCY-247 to address the serious unmet need posed by life-threatening resistant fungal infections,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “Last year we presented results from multiple preclinical efficacy models consistently showing the potent antifungal activity of SCY-247 against a broad array of
Show less
Read more
Impact Snapshot
Event Time:
SCYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCYX alerts
High impacting SCYNEXIS, Inc. news events
Weekly update
A roundup of the hottest topics
SCYX
News
- SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)GlobeNewswire
- SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247GlobeNewswire
- SCYNEXIS granted Nasdaq extension to regain bid price compliance [Seeking Alpha]Seeking Alpha
- SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement [Yahoo! Finance]Yahoo! Finance
- SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementGlobeNewswire
SCYX
Earnings
- 11/5/25 - Beat
SCYX
Sec Filings
- 2/2/26 - Form 4
- 2/2/26 - Form 4
- 2/2/26 - Form 4
- SCYX's page on the SEC website